Skip to content

Welcome to Discover Pharma! Today is : November 16, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

acute myeloid leukaemia

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Inaqovi combination wins EU approval for AML treatment

    Otsuka Pharmaceutical Europe has received an amended European Commission marketing [...]

    July 2, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Otsuka secures EU approval for Inaqovi combination therapy in acute myeloid leukaemia

    Inaqovi in combination with venetoclax has received an amended European [...]

    June 24, 2026
  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg presents preclinical POLB 001 data at EHA Congress

    Poolbeg Pharma has presented two posters at the European Hematology [...]

    June 11, 2026
  • Biotech & Pharma Business,Drug Discovery & Development

    AmMax licenses Lonza ADC technology for AML programme

    AmMax Bio has licensed antibody-drug conjugate technology from Lonza to [...]

    June 10, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Otsuka submits EMA application for Inaqovi and venetoclax combination to treat acute myeloid leukaemia

    Otsuka Pharmaceutical Europe has submitted a marketing authorisation application (MAA) [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Commit Biologics nominates first complement engager drug candidate
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Research & Development, Therapeutic Areas
  • Caristo AI detects hidden cardiovascular risk in 19,110-patient study
    Categories: Digital & Data, Medical devices, Research & Development, Therapeutic Areas
  • Mogrify reports retinal regeneration results in preclinical study
    Categories: Advanced Therapies, Drug Discovery & Development, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top